Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy

Anti-Cancer Drugs

Volumn 23, Issue 3, 2012, Pages 326-334

  Miscoria, Manuela ^a   Tonetto, Fabrizio ^a   Deroma, Laura ^a   Machin, Piernicola ^a   Di Loreto, Carla ^a   Driol, Pamela ^a   Minisini, Alessandro Marco ^a   Russo, Stefania ^a   Andreetta, Claudia ^a   Mansutti, Mauro ^a   Damante, Giuseppe ^a   Fasola, Gianpiero ^a   Puglisi, Fabio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Advanced breast cancer; Angiogenesis; Metronomic chemotherapy; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; METHOTREXATE; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; METRONOMIC DRUG ADMINISTRATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST PROGRESSION SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADMINISTRATION, METRONOMIC; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858289650     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834e735a     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300. Erratum in: CA Cancer J Clin 2011; 61:133-134.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
3. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29:456-463.
4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:966-978.
5. Andreetta C, Minisini AM, Miscoria M, Puglisi F. First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 2010; 76:99-111.
6. Puglisi F, Cardoso F, Lebrun F, Piccart M. First-line treatment of metastatic breast cancer: available evidence and current recommendations. Am J Cancer 2006; 5:99-110. (Pubitemid 47194453)
7. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behaviour of breast cancer subtypes. J Clin Oncol 2010; 28:3271-3277.
8. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 2011. Published on 16 Febraury 2011. doi:10.1016/j.critrevonc. 2011.01.010.
9. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800.
10. Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011; 22:1000-1010.
11. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-465.
12. De Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006; 59:40-50. (Pubitemid 43903280)
13. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005; 16:1243-1252. (Pubitemid 41166506)
14. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73-80. (Pubitemid 34436728)
15. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17:961-967. (Pubitemid 44350615)
16. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17:232-238. (Pubitemid 43160111)
17. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108:452-459. (Pubitemid 44061341)
18. Burstein HJ, Spiegel D, Kinds Vogel K, Parker LM, Bunnell CA, Partridge AH, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005; 95:58.
19. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-436. (Pubitemid 38745528)
20. Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 2007; 39:150-159.
21. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2002; 105:1045-1047. (Pubitemid 30217688)
22. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966-4972.
23. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-3247.
24. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-1260.
25. Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011; 30:54.
26. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6:158-166. (Pubitemid 40309127)
27. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63:527-533. (Pubitemid 36152517)
28. Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K. Thymidine phosphorylase and breast carcinoma. Anticancer Res 2002; 22:2355-2360. (Pubitemid 34857065)
29. Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, et al. Prognostic impact of thymidine phosphorylase expression in breast cancer - Comparison of microarray and immunohistochemical data. Eur J Cancer 2010; 46:549-557.
30. Puppin C, Puglisi F, Pandolfi M, Di Loreto C, Damante G. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines. Oncol Rep 2011; 26:309-314.
31. Tsuda H, Akiyama F, Kurosumi M, Sakamoto G. Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue. Breast Cancer Res Treat 2004; 86:215-223. (Pubitemid 39070964)
32. Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, et al. Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 2011; 104:1185-1192.
33. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82:1427-1432. (Pubitemid 30175909)
34. Puglisi F, Andreetta C, Valent F, Minisini AM, Rijavec E, Russo S, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18:883-888. (Pubitemid 47220706)
35. Andreetta C, Puppin C, Minisini A, Valent F, Pegolo E, Damante G, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 2009; 20:265-271.
36. Puglisi F, Cardellino GG, Crivellari D, Di Loreto C, Magri MD, Minisini AM, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 2008; 19:1541-1546.
37. Jassem J, Carroll C, Ward SE, Simpson E, Hind D. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 2009; 45:2749-2758.
38. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101:1642-1649.
39. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28:1958-1962.
40. Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011; 16:25-35.
41. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus Bevacizumab. Clin Cancer Res 2009; 15:7652-7657.
42. Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 2007; 110:509-517. (Pubitemid 47106138)
43. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011; 17:372-381.